Abstract: Objective To observe the effect of Sacubitril/valsartan, in comparison to benazepril, in the treatment of patients with heart failure after acute myocardial infarction(AMI), so as to improve the prognosis. 
Methods A total of 86 patients with heart failure after AMI undergoing percutaneous coronary intervention(PCI) were selected. According to different treatment methods, they were divided into control group(benazepril) and observation group(Sacubitril/valsartan), with 43 cases in each group. At 3 months after operation, echocardiographic data［left ventricular end-systolic volume(LVESV), left ventricular end-diastolic volume(LVEDV), left ventricular ejection fraction(LVEF), stroke volume(SV)］, serum inflammatory factors［high-sensitivity C-reactive protein(hs-CRP), interleukin-6(IL-6)］, N-terminal pro-B-type natriuretic peptide(NT-proBNP), 6-min walking test, adverse reactions, prognosis and outcome were compared. 
Results After treatment, LVESV and LVEDD in the two groups were lower than those before treatment, and LVEF and SV were higher than those before treatment. However, LVESV and LVEDD in the observation group were lower than those in the control group, and LVEF and SV were higher than those in the control group, with statistically significant differences(P＜0.05). The levels of hs-CRP, IL-6 and NT-proBNP in the two groups were lower than those before treatment, which were lower in the observation group than in the control group, with statistically significant differences(P＜0.05). There was no statistically significant difference in the incidence of adverse reactions, such as hypotension, hyperkalemia and renal insufficiency between the two groups(P＞0.05). There was no statistically significant difference in recurrent myocardial infarction, ventricular tachycardia/frequent ventricular premature beats and sudden cardiac death between two groups(P＞0.05). The re-hospitalization rate of patients with heart failure in the observation group was lower than that in the control group, and the 6-min walking test in the observation group was longer than that in the control group, with statistically significant differences(P＜0.05). 
Conclusion Compared with benazepril, Sacubitril/valsartan can improve left ventricular function and left ventricular remodeling in patients with heart failure after myocardial infarction, increase its activity tolerance, and reduce the rate of re-hospitalization for heart failure, but will not increase the incidence of adverse reactions and adverse cardiovascular events. 

Key words: myocardial infarction, heart failure, sacubitril/valsartan